NEWS
The NHS Tries Multi-Cancer Blood Tests Where Screening Stumbled
The NHS is trying multi-cancer blood tests in 200 GP surgeries on patients who already feel unwell, after Galleri failed to cut late-stage diagnoses.
More than 20,000 NHS patients with vague abdominal symptoms will be offered multi-cancer blood tests at some 200 GP surgeries in England. The STRIDE-RCT trial, led by the University of Birmingham and funded by the NIHR, is built to spot hard-to-find cancers of the gut, liver, ovaries and nearby organs while they are still treatable.
It is easy to hear that as the long-promised cancer blood test arriving at the GP. It is a narrower bet. The patients already feel unwell. The tests are there to help a GP decide who needs a scan, after a much larger screening study in people with no symptoms failed to cut late-stage disease.
200 GP Surgeries Will Draw Extra Tubes of Blood
Eligible patients are aged 45 and over and present with symptoms such as pain or persistent bloating, the kind of complaints that can be irritable bowel one week and ovarian or pancreatic cancer the next. They will give one or two extra tubes of blood at the practice, taken with routine tests, and scientists will look for proteins or fragments of DNA that may signal cancer and, if a signal is present, suggest where in the body it started.
Prof Peter Johnson, NHS England’s national clinical director for cancer, said detecting abdomen cancer early was “notoriously difficult” because the symptoms can easily be mistaken for milder conditions. Around 71,000 people in England are diagnosed each year with pancreatic, stomach, liver, ovarian or bowel cancer, and nearly 35,000 die from those five diseases. STRIDE’s protocol is wider than that list.
CANCERS THE TRIAL IS BUILT TO FIND
- Digestive tract: Bowel, small bowel, stomach, oesophageal, pancreatic, liver, bile duct and gallbladder.
- Gynaecological: Ovarian and endometrial.
- Urinary and prostate: Kidney, bladder and prostate.
That is 13 cancer types in total. A positive result does not automatically mean there is cancer, and a negative result is not a guaranteed all-clear. Health secretary Yvette Cooper said she hoped simple blood tests of this kind would help identify patients who need urgent investigation much sooner. Michelle Mitchell of Cancer Research UK said GPs have long needed better tools for that uncertainty, and called the English trial “an important step towards addressing that need.”
The cluster trial running until 2031 opened its window on 1 November 2026 and is listed as active, with Aneel Bhangu, a consultant colorectal surgeon at the University of Birmingham, as principal investigator. Launch coverage said the study will evaluate tests from three companies. The public protocol still has to prove they are accurate enough for wider NHS use.
The Screening Trial Did Not Cut Late-Stage Disease
The idea of one blood test for many cancers is not new inside the NHS. NHS-Galleri enrolled people aged 50 to 77 who had no cancer symptoms, randomised 142,250 of them, and added the Galleri assay, made by GRAIL, to usual care for three annual rounds. The primary paper found no reduction in combined stage 3 and 4 diagnoses among 12 pre-set cancer types. The incidence rate ratio was 1.03 (0.92 to 1.14), p=0.63.
Charles Swanton, co-chief investigator, said the study tested whether the blood test could reduce the combined number of cancers diagnosed at stage 3 or 4 over three years, and that the study did not meet its main goal. A secondary look at stage 4 alone was kinder to the test. The incidence rate ratio after three rounds was 0.86 (0.74 to 1.00), about 14% fewer of the most advanced cancers overall. In the second and third rounds, the trial team said there were at least 20% fewer stage 4 diagnoses, and for 12 fast-growing types the shortfalls were 9% in round one, 22% in round two and 26% in round three.
Stage 1 and 2 diagnoses were 16% higher in people who had the test, including some cancers often found late, such as ovarian, oesophageal, pancreatic and liver. Adding the blood test to usual NHS screening for breast, bowel, cervical and high-risk lung cancer found four times more cancers than those programmes alone. Fewer cancers turned up as emergencies. None of that rescued the headline target the trial was built around, which is why a missed screening endpoint still hangs over every new multi-cancer blood test the NHS announces.
HOW THE NHS GOT TO A GP TRIAL
- August 2021: NHS-Galleri begins recruiting people aged 50 to 77 with no symptoms.
- July to November 2021: SYMPLIFY enrols people already referred from primary care with suspected cancer.
- 30 May 2026: Full Galleri results show no cut in combined stage 3 and 4 disease.
- 22 September 2026: The primary analysis is published, with 142,250 people randomised.
- 1 November 2026: STRIDE-RCT’s window opens in English GP surgeries.
Johnson is on both projects. He is an author on the Galleri primary paper and the NHS cancer director quoted on STRIDE. The service is not walking away from multi-cancer blood tests. It is moving them from a mobile screening van into the room where bloating and belly pain are sorted.
SYMPLIFY Already Tested This Idea in Referred Patients
A screening miss does not settle whether the same class of assay can help a GP. Oxford’s SYMPLIFY study asked that older, smaller question in people who had already been sent for urgent tests. It enrolled 6,238 people with suspected cancer in England and Wales and analysed 5,461 with a usable Galleri result and a final diagnosis. Standard NHS tests found cancer in 368 of them, or 6.7%.
The blood test flagged a cancer signal in 323 people, 244 of whom had cancer, a positive predictive value of 75.5%. Sensitivity was 66.3% overall and rose with stage, from 24.2% in stage 1 to 95.3% in stage 4. Specificity was 98.4% and the negative predictive value 97.6%. When the test was right about cancer, its best guess at the starting organ was accurate in 85.2% of those cases. Follow-up in 2025 on the 79 people who had a positive test but no cancer within nine months found that 28 of them, 35%, were diagnosed with cancer within two years.
The use of MCED testing, with an accurate prediction of the site of origin in symptomatic patients can speed up diagnosis where we are not sure which diagnostic pathway is the right one.
Mark Middleton, head of oncology, University of Oxford, on SYMPLIFY
Those numbers looked stronger than screening because the patients were already in a high-risk queue. STRIDE walks the test back a step, into ordinary GP lists, where the share of people with cancer will be lower than 6.7% and a positive result will therefore catch more people who do not have a tumour. That is the trade the new trial has to measure, not a rerun of Galleri’s stage 3 and 4 scoreboard.
THREE TRIALS, THREE JOBS
| Trial | Who was tested | Size | The question | What is known |
|---|---|---|---|---|
| NHS-Galleri | People aged 50 to 77 with no symptoms | 142,250 randomised | Cut combined stage 3 and 4 disease? | No. IRR 1.03, p=0.63 |
| SYMPLIFY | People already referred with symptoms | 5,461 analysed | Can the test spot cancer and its site? | PPV 75.5%, sensitivity 66.3% |
| STRIDE-RCT | GP patients aged 45+ with vague abdominal symptoms | More than 20,000 at some 200 surgeries | Accurate enough for wider NHS use? | Running 1 November 2026 to 31 October 2031 |
Informed argument after Galleri split along that table’s first row, with one camp treating a missed endpoint as a failed screen and another pointing at fewer stage 4 cases and calling the target the wrong one. STRIDE does not wait for that fight to end. It asks the second row’s question one step earlier, in the practice rather than the rapid-referral clinic.
One Test Reads Immune Proteins, Another Reads Tumour DNA
Launch briefings said STRIDE will put three assays side by side. Two were named. Enlighten, from the Cambridge firm Proteotype Diagnostics, does not hunt for DNA shed by a tumour. It looks for immune response protein signatures that appear when the body reacts to early cancer, using coloured light readings from plasma amino acids and a machine-learning score. Andy Davies, who leads a separate Southampton evaluation of the same assay, has said circulating tumour DNA cannot always be found in the earliest stages, which is why the protein route is being tried at all.
Signatera is a different animal. It is already used in the NHS to look for leftover tumour DNA after treatment, and NICE has reviewed it as a test for residual disease after solid tumours. Classic Signatera is built from a patient’s own tumour tissue, then used as a blood monitor. Using a leftover-disease assay in people who have not yet had a cancer confirmed is a much harder ask than watching someone whose tumour has already been sequenced, and the trial will have to show what version of the test is actually in the GP tube.
The third company’s product has not been named in the public launch material. Until it is, the honest description is a platform trial of several blood tests, some reading immune proteins and some reading tumour DNA, sitting next to the GP’s usual bloods. That mix is the point of a cluster platform: different tools, one NHS question.
Most Urgent Referrals Still Come Back Clear
Bhangu has spent his clinic seeing the two failures that STRIDE is meant to shrink. Patients with real cancers arrive late, after months of symptoms that never quite fitted a two-week-wait box. At the same time, most people sent urgently do not have cancer, which loads clinics, scans and waiting rooms with fear that was never going to end in an oncology letter.
Too many patients with cancer reach me after months of vague symptoms that were hard to pin down. At the same time, most people referred urgently do not have cancer, causing unnecessary worry and expense. These blood tests might help GPs tell the two apart, but we need to know for certain before they are used across the NHS, and this trial is designed to give that answer quickly.
Aneel Bhangu, consultant colorectal surgeon and STRIDE-RCT lead, University of Birmingham
A blood test that is only fairly specific will still manufacture extra work. SYMPLIFY’s 75.5% positive predictive value applied to people already referred. In a GP list the same chemistry will flag more people who then need a CT, an MRI, an endoscopy or a specialist slot they may not have needed. On 3 November 2026, the day before STRIDE was made public, the health department said 125 extra CT and MRI scanners since March 2024 were helping the NHS deliver a million extra scans a year. Capacity is rising. It is also the bucket that false positives fall into.
WHAT A POSITIVE BLOOD TEST CAN TRIGGER
- A harder conversation: The GP still has to explain that a signal is not a diagnosis, and that a wait for scans is now on the table.
- Urgent tests: Imaging, endoscopy or a two-week clinic, aimed at the organ the assay guesses, which SYMPLIFY showed is not always the organ the symptoms pointed at.
- A negative that cannot close the case: Stage 1 sensitivity in SYMPLIFY was 24.2%, so a clear blood test cannot send a still-unwell patient home as fine.
That cascade, not the romance of a single tube, is what a GP trial is for. If the assays sort the bloated from the truly high-risk without flooding radiology, they earn a wider roll-out. If they mainly reprint the GP’s existing hunch, or multiply inconclusive scans, they stay in the lab.
What Would Count as a Useful Result?
The protocol’s own test is whether the blood tests are accurate enough for wider NHS use, used alongside a GP’s judgement rather than instead of it. Launch notes said GPs may record how strongly they already suspect cancer, so researchers can see whether the tube adds anything to a raised eyebrow and a history. Survival is the hope Cooper voiced. It is not a result this trial can mint in a year.
WHAT WE KNOW
- The setting: Some 200 English GP surgeries, more than 20,000 patients aged 45 and over, one or two extra tubes beside routine bloods.
- The cancers: 13 types, with pancreatic, ovarian and liver among those often found after they have spread.
- The recent screen: NHS-Galleri did not reduce combined stage 3 and 4 diagnoses in 142,250 people with no symptoms.
WHAT IS UNCONFIRMED
- Accuracy in GP lists: No STRIDE performance figures exist yet, and SYMPLIFY’s 75.5% predictive value was measured after referral, not before it.
- The third assay: Three companies are in the trial; only Enlighten and Signatera have been named in launch material.
- National use: Wider NHS adoption is the question the five-year study is meant to answer, not a decision already taken.
A useful result would be a test that lifts the chance a GP refers the right person, names a plausible organ so the first scan is the right scan, and does not send a crowd of worried well into CT queues. A useless result would be high sensitivity only once cancer is already late, or a pile of positives that cannot be localised. STRIDE is allowed to return either answer. The political mood music around “simple blood tests” will not.
GPs Will Still Decide Who Goes for a Scan
For the patient in the chair, the visit will look ordinary. Blood is already part of the work-up for persistent bloating. The difference is a second tube and a later call that may push the GP toward an urgent referral, or may not. Cooper’s hope is that this identifies people who need support much sooner. Bhangu’s warning is that the NHS has to know that before it uses the tests everywhere.
The screening product and the GP product share a laboratory family and almost none of their clinical job. Galleri was asked to shift the stage of cancer in people who felt fine, and on its own primary measure it did not. STRIDE asks whether proteins and DNA fragments can help a GP split cancer from the far larger group of people with the same stomach-ache. That is a humbler claim. It is also the one earlier symptomatic work, including SYMPLIFY, gave some reason to test.
Until 31 October 2031, a positive STRIDE result remains a reason for more tests, and a negative result is not an all-clear. The extra tubes will keep leaving English GP rooms either way.
Disclaimer: This article is news reporting and analysis of a clinical trial and related studies. It is for information only and is not medical advice, a diagnosis, or a recommendation to seek or skip any test, scan or referral. Readers with symptoms, or questions about cancer testing, should speak to their GP or another qualified clinician who can assess their own history. Figures, trial status and test names reflect the public sources available on 4 November 2026 and may change as STRIDE-RCT and related studies report results.
-
NEWS2 months agoAI Server Boards Put Everyday Circuit Materials on Allocation
-
NEWS3 months agoGlacier Collapse Buried Nepal’s Hydropower Workers in Tunnels
-
NEWS3 months agoCongo’s Bundibugyo Outbreak Outruns the Licensed Ebola Shots
-
NEWS3 months agoPennsylvania Measles Deaths Follow a Long Slide in Coverage
-
NEWS3 months agoCISA’s Known Exploits Still Come From 2007-Era Bugs
-
NEWS3 months agoTexas Judge Freezes the SEC Eligibility Ban for 41 Athletes
-
NEWS3 months agoGermany Can Miss Its 2026 Climate Cap Without Penalty
-
GAMING2 months agoXbox Disc-to-Digital Turns Delisted Games Into Traveling Licenses
